COVID HOME

Description

Longitudinal COVID-19 population cohort that was initiated during the COVID-19 pandemic in 2020 and continued until 2024. Enrolled participants were visited at home within 48-hours of diagnoses and followed-up over the next three weeks to collect cli

General Design

Type: Cohort study
Cohort type: Population cohort
Design description: A prospective longitudinal observational study of COVID-19 outpatients was established in March 2020 at the beginning of the COVID-19 pandemic in the Netherlands. Laboratory confirmed SARS-CoV-2 infected individuals of all ages that did not merit hospitalisation, and their household (HH) members, were enrolled after written informed consent. Enrolled participants were visited at home within 48 hours after initial diagnosis, and then weekly on days 7, 14 and 21 to obtain clinical data, a blood sample for biochemical parameters/cytokines and serological determination; and a nasopharyngeal/throat swab plus urine, stool and sperm or vaginal secretion (if consenting) to test for SARS-CoV-2 by RT-PCR (viral shedding) and for viral culturing. Weekly nasopharyngeal/throat swabs and stool samples, plus a blood sample on days 0 and 21 were also taken from HH members to determine whether and when they became infected. All participants were invited to continue follow-up at 3-, 6-, 12- and 18-months post-infection to assess long-term sequelae and immunological status.
Start/End data collection: 2020 until 2024
PID: https://doi.org/10.34760/6800d78bd68ec

Population

Countries: Netherlands (the)
Regions: Drenthe, Friesland, Groningen
Number of participants: 270
Population age groups: All ages
Other inclusion criteria: "Onset of symptoms <5 days before inclusion, Positive diagnostic RT-PCR for SARS-CoV-2 performed within 48h of inclusion, Index person should supply all required samples in the protocol for the duration of the study, All HH members should join the study, Signing of informed consent form"

Organisations

Lead organisations

University Medical Center Groningen (UMCG)
Netherlands (the)
https://www.umcg.nl

Contributors

COVID HOME Contacta.tami@umcg.nl
Primary contact

Access conditions

After approval by PI and study coordinators

After approval by PI and study coordinators...

Data access fee: false

Funding & Acknowledgements

Funding: The project received funding from the Netherlands Organisation for Health Research and Development (ZonMw)[23] , grant 10430012010023, and as partner of the ORCHESTRA project [24] which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016167.
Acknowledgements: We would like to firstly thank all the participants of the COVID HOME study for their ongoing contribution to the project and to the understanding of COVID-19. Our thanks also go to the Clinical Virology (Molecular and Serology) unit and to the Infection Prevention section, in special to Jet van der Weerd (Head of Infection Prevention), all part of the Department of Medical Microbiology & Infection Prevention, UMCG; as well as Lars van Heerden (manager) and the staff from the Laboratory of General Haematology and Chemistry, Laboratory Medicine, UMCG; to Myke Mol and Paul Koenes from the Service Desk Clinical Research Office, UMCG, the Netherlands; and to Cesar Cuadra, microbiologist, for invaluable support during writing of the study protocol. Lastly, we would like to thank the collaboration of the Municipal Public Health Services (GGD) of Groningen and Drenthe with the recruitment of study participants in this region.